Thank you to all our speakers who presented at SCC2010. Please find below a list of the international keynote and local speakers.
- Professor Charles S. Cleeland, The University of Texas, USA, and the WHO
- Professor Patrick MM Bossuyt, University of Amsterdam, the Netherlands
- Dr Nadia Zaffaroni, National Cancer Institute, Italy
Confirmed invited speakers
- Bruce Armstrong, The University of Sydney
- Suzanne Cory, Walter & Eliza Hall Institute of Medical Research, Melbourne
- Sally Crossing, Cancer Voices NSW
- David Currow, Cancer Institute NSW
- Elizabeth Eakin, The University of Queensland, Brisbane
- Afaf Girgis, The University of Newcastle, Australia
- Doug Hilton, Walter & Eliza Hall Institute of Medical Research, Melbourne
- Peter Hudson, AviPep Pty Ltd, Melbourne
- Madeleine King, The University of Sydney
- Jennifer MacDiarmid, EnGeneIC Pty Ltd, Sydney
- Graham Mann, The University of Sydney
- Stephen Mulligan, Kolling Institute of Medical Research and Royal North Shore Hospital
- Andrew Roberts, Walter & Eliza Hall Institute of Medical Research, Melbourne
- Monica Robotin, The University of Sydney and Cancer Council NSW
- John Simes, The University of Sydney
- Martin Stockler, The University of Sydney
- David Thomas, Peter MacCallum Cancer Centre, Melbourne
- Matt Trau, The University of Queensland, Brisbane
- Brandon Wainwright, The University of Queensland, Brisbane
- Robyn Ward, The University of New South Wales, Sydney
- David Ziegler, The University of New South Wales, Sydney
Professor Charles S. Cleeland
McCullough Professor of Cancer Research and Chair,
The University of Texas, USA
Director, WHO Collaborating Center for Supportive Cancer Care
Professor Charles Cleeland is McCullough Professor of Cancer Research at the MD Anderson Cancer Center and the recipient of the American Pain Society’s 2002 Fordyce Clinical Investigator Award. He is a leader in the area of cancer symptom epidemiology, assessment and treatment. He has directed epidemiological studies of pain and other symptoms in patients with cancer, studies of the mechanisms of pain and other symptoms, studies using PET and functional MRI to examine the effects of pain on cortical activity, and clinical trials aimed at reducing the risk of inadequate symptom control.
He currently serves as Director and Chair of the Scientific Advisory Board of the American Pain Foundation and is Senior Scientific Advisor of the Pan American Health Organization/WHO. He has published numerous studies on the prevalence and severity of cancer pain, of U.S. and international symptom management practice patterns, and of patient, public and professional attitudes toward cancer pain and its treatment.
Professor Patrick MM Bossuyt
Professor of Clinical Epidemiology
Academic Medical Center
University of Amsterdam, the Netherlands
Patrick M. Bossuyt, PhD is the professor of Clinical Epidemiology at the University of Amsterdam and for the past 10 years he has Chaired the department of Clinical Epidemiology, Biostatistics and Bioinformatics at that University. Patrick Bossuyt obtained a Master’s level degree in Psychology from the University of Gent (Belgium) and a PhD from the University of Nijmegen (Netherlands) in 1990.
Before his present appointment Bossuyt worked at the Center for Clinical Decision Making of the Erasmus University in Rotterdam, supporting clinical research projects in what is now Erasmus Medical Center. In 1991 Bossuyt moved to the then just founded Department of Clinical Epidemiology and Biostatistics of the Academic Medical Center of the University of Amsterdam. Since 2006 he has served as Dean of Graduate Studies at his institution.
His scientific work mirrors that of the department, covering a broad range of topics in clinical research, developed in close collaboration with clinical departments. In his work there is an emphasis on research on the effectiveness of clinical interventions and medical technology assessment. With several other members of his department Professor Bossuyt shares a special interest in the methodology for evaluating medical tests. He spearheaded the STARD initiative for the improved reporting of diagnostic test accuracy studies and has acquired multiple grants on test evaluation methods.
Professor Bossuyt has authored and co-authored more than 450 publications in peer reviewed journals and serves on the editorial board of a number of these, including Radiology and Clinical Chemistry. His publications have appeared in the Lancet (14), BMJ (13), New England Journal of Medicine (7) and many other journals. He has supervised more than 50 successful PhD theses. Dr Bossuyt is a member of the Dutch Health Council and several national and international advisory committees.
Dr Nadia Zaffaroni
Department of Experimental Oncology
National Cancer Institute, Milan, Italy
Dr Nadia Zaffaroni graduated with honours in Biological Sciences at the University of Milan in 1980 and received her Ph.D. in 1990 from the same University. She is team leader within the Translational Research Unit in the Department of Experimental Oncology at the Fondazione IRCCS National Cancer Institute (Istituto Nazionale dei Tumori) of Milan, Italy. From 2006-2009, she served as Chairperson of the Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer (EORTC).
Her main area of investigation concerns translational research and is focused on the definition of new biomarkers (mainly related to telomere maintenance mechanisms and apoptosis pathways) and the validation of new therapeutic targets. In the context, her research group gained a recognized experience in the design, synthesis and development of gene-silencing approaches targeting telomerase and other tumor cell survival factors as well as in the development of strategies for the intracellular delivery of these molecules.
More recently, she has focused on the expression and functional role of microRNAs in prostate cancer with the aim to identify new therapeutic targets for advanced disease. In this context, her research group identified miR-205 as an oncosuppressor microRNA in the disease, able to counteract epithelial-to-mesenchymal transition mainly through the down-regulation of protein kinase Cepsilon.